Ticiana A. Leal, MD

A panel of experts discusses the testing and targeting of HER2 in non-small cell lung cancer (NSCLC) and the impact of recent clinical trial data on treatment selection.

Before closing her discussion on advanced non–small cell lung cancer, Ticiana Leal, MD, highlights the possible role of immunotherapy in patients with concomitant KRAS/TP53 mutations.

A brief review of the lack of efficacy seen with immunotherapy approaches in patients with EGFR-mutated or ALK-rearranged non–small cell lung cancer.

After highlighting major barriers to molecular testing in advanced non–small cell lung cancer, Ticiana Leal, MD, provides advice on how to circumvent issues in this setting.

Considerations for optimizing the use of molecular testing in advanced non–small cell lung cancer, addressing insufficient tissue collection and liquid biopsy approaches.

Expert Ticiana Leal, MD, shares her perspective on routine molecular testing practices in advanced non–small cell lung cancer.

Ticiana Leal, MD, discusses the utilization of PD-1 and PD-L1 inhibitor monotherapy in lung cancer.

Ticiana Leal, MD, discusses the evolution of treatment in EGFR exon 20 insertion–positive non–small cell lung cancer.

Ticiana Leal, MD, discusses developments made in the treatment of patients with EGFR exon 20 insertion–mutant non–small cell lung cancer.

Ticiana A. Leal, MD, discusses the rationale for the phase 2 ECOG-ACRIN EA5161 trial in extensive-stage small cell lung cancer.

Increasing evidence suggests that immune responses against SCLC cells make immunotherapy a rational approach.